Among them, the combination of ICB and TKI, such as some fixed treatment modes such as Cabozantinib and Atezolizumab(PD-L1), Cabozantinib and Nivolumab(PD-1) and Ipilimumab(CTLA-4), Lenvatinib and Pembrolizumab(PD-1) are still feasible ideas for the treatment of thyroid cancer. The gene discussed is CTLA4; the disease is thyroid cancer.